Cardiol Therapeutics Reports Q1 2026 Results, $27.7M Cash, and Extends Runway into Q4 2027

summarizeSummary

Cardiol Therapeutics reported its Q1 2026 financial results, showing a robust cash balance of $27.7 million, which is projected to fund operations into Q4 2027. The company also announced that its pivotal Phase III MAVERIC trial has reached 75% patient enrollment.

check_boxKey Events

• Strong Cash Position and Extended Runway

  Cardiol Therapeutics reported cash and cash equivalents of $27,673,191 as of March 31, 2026, up from $21,416,684 at year-end 2025. This cash position is expected to fund operations and capital requirements into Q4 2027, providing significant financial stability.

• Progress in Pivotal Phase III MAVERIC Trial

  Patient enrollment in the pivotal Phase III MAVERIC trial for recurrent pericarditis has reached 75%. Target recruitment is anticipated by the end of Q2 2026, with potential extension into Q3 2026 to accommodate additional clinical sites.

• Q1 2026 Financial Results

  The company reported a net loss of $10,818,589 for the three months ended March 31, 2026, compared to a net loss of $8,287,653 for the same period in 2025. Research and development expenses increased to $4,949,411, reflecting ongoing clinical trial activity.

• January 2026 Financing Confirmed

  The company confirmed the closing of a bought deal financing in January 2026, which generated gross proceeds of $14.85 million. This financing contributed to the improved cash balance.

auto_awesomeAnalysis

This filing provides the Q1 2026 financial results, highlighting a strengthened cash position following a January 2026 financing. The company now has sufficient capital to fund operations into Q4 2027, which is a critical positive for a clinical-stage biotech. Significant progress in the pivotal Phase III MAVERIC trial, with 75% patient enrollment, further de-risks the clinical development pathway.